Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2022 - 01 - 24 save search
Lyell Immunopharma Announces FDA Clearance of IND for LYL132
Published: 2022-01-24 (Crawled : 16:00) - biospace.com/
LYEL | $2.24 -3.86% -4.02% 1.1M
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 4.78%
C: 3.82%
lyl132 fda clearance fda clearance
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
Published: 2022-01-24 (Crawled : 14:30) - biospace.com/
CDXS | $2.815 0.54% 0.53% 470K
|
Process Industries
|
| O: -9.93%
H: 7.09%
C: 6.37%
treatment fda rare drug disease rare pediatric disease designation orphan drug designation
Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates
Published: 2022-01-24 (Crawled : 13:30) - biospace.com/
TNGX | $7.33 -0.54% -0.55% 530K
|
|
| O: 0.95%
H: 6.24%
C: 2.82%
tng908 fda clearance therapeutics
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -1.26%
H: 0.0%
C: -6.82%
tsc-100 new drug treatment fda ema clearance application drug therapeutics fda clearance 100 scan
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
HCWB | $1.66 0.0% 1.4K
|
|
| O: 5.45%
H: 0.47%
C: 0.0%
hcw9218 fda clearance solid tumors trial fda clearance phase 1 cancer
Ionis announces eplontersen receives orphan drug designation from U.S. FDA
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -1.45%
H: 7.89%
C: 7.31%
fda drug orphan drug designation eplontersen
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 1.39%
H: 6.65%
C: 6.09%
treatment fda drug orphan drug syndros designation
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
Published: 2022-01-24 (Crawled : 12:00) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: -3.62%
H: 7.66%
C: 6.27%
hpv16 new drug treatment fda clearance solid tumors application hpv drug cel fda clearance positive therapy biotech iot
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.